Dali Pharmaceuticalco.,Ltd
SSE:603963.SS
1.18 (CNY) • At close February 7, 2025
Overzicht | Financiële gegevens
Cijfers zijn in miljoenen (behalve de cijfers per aandeel en de ratio's) CNY.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Omzet
| 87.27 | 132.344 | 171.493 | 213.583 | 294.325 | 401.483 | 272.739 | 275.765 | 266.965 | 338.686 | 297.65 | 285.268 |
| Kosten van de omzet
| 50.973 | 57.786 | 45.943 | 57.066 | 73.216 | 79.432 | 87.752 | 146.946 | 143.173 | 172.854 | 141.757 | 127.582 |
| Brutowinst
| 36.297 | 74.558 | 125.55 | 156.518 | 221.109 | 322.051 | 184.987 | 128.818 | 123.792 | 165.833 | 155.893 | 157.686 |
| Brutowinstmarge
| 0.416 | 0.563 | 0.732 | 0.733 | 0.751 | 0.802 | 0.678 | 0.467 | 0.464 | 0.49 | 0.524 | 0.553 |
| Onderzoek- en ontwikkelingskosten
| 0.84 | 0.927 | 1.441 | 2.829 | 2.23 | 2.239 | 2.868 | 3.976 | 3.108 | 2.425 | 5.501 | 2.86 |
| Algemene en administratieve kosten
| 5.232 | 5.051 | 19.808 | 9.44 | 7.511 | 16.464 | 10.818 | 8.847 | 7.319 | 5.44 | 19.862 | 16.715 |
| Verkoop- en marketingkosten
| 39.776 | 73.686 | 100.791 | 128.532 | 184.213 | 270.91 | 107.176 | 23.372 | 22.17 | 21.525 | 21.873 | 26.84 |
| Verkoop-, algemene en administratieve kosten
| 45.008 | 78.736 | 120.599 | 137.973 | 191.725 | 287.374 | 117.995 | 32.219 | 29.49 | 26.965 | 41.735 | 43.555 |
| Overige kosten
| 3.598 | 17.291 | 16.741 | 17.348 | 16.767 | 0.997 | 6.592 | 0.655 | -0.275 | -0.054 | 4.059 | 0.704 |
| Bedrijfskosten
| 53.332 | 96.955 | 138.781 | 158.15 | 210.722 | 312.08 | 136.269 | 56.079 | 51.099 | 48.117 | 44.581 | 47.323 |
| Bedrijfsresultaat
| -17.035 | -22.397 | -9.33 | -2.362 | 15.955 | 11.622 | 45.743 | 72.401 | 73.395 | 118.009 | 111.816 | 110.441 |
| Bedrijfsresultaat ratio
| -0.195 | -0.169 | -0.054 | -0.011 | 0.054 | 0.029 | 0.168 | 0.263 | 0.275 | 0.348 | 0.376 | 0.387 |
| Totaal overige inkomsten en kosten netto
| -0.333 | 0.169 | -1.787 | -1.877 | 1.168 | 0.997 | 6.592 | 0.649 | -0.275 | -0.361 | -3.806 | 0.639 |
| Inkomen voor belasting
| -17.368 | -16.998 | -41.592 | 3.776 | 17.123 | 12.619 | 52.335 | 73.049 | 73.12 | 117.648 | 108.01 | 111.085 |
| Inkomen voor belasting ratio
| -0.199 | -0.128 | -0.243 | 0.018 | 0.058 | 0.031 | 0.192 | 0.265 | 0.274 | 0.347 | 0.363 | 0.389 |
| Belastingkosten
| 2.663 | 0.704 | 0.299 | 0.544 | 3.618 | 1.918 | 7.883 | 10.884 | 10.828 | 17.578 | 15.978 | 16.491 |
| Nettowinst
| -20.031 | -17.702 | -41.891 | 3.232 | 13.505 | 10.7 | 44.452 | 62.166 | 62.293 | 100.07 | 92.032 | 94.594 |
| Nettowinstmarge
| -0.23 | -0.134 | -0.244 | 0.015 | 0.046 | 0.027 | 0.163 | 0.225 | 0.233 | 0.295 | 0.309 | 0.332 |
| WPA (Winst Per Aandeel)
| -0.09 | -0.081 | -0.19 | 0.015 | 0.062 | 0.046 | 0.3 | 0.38 | 0.46 | 0.91 | 0.84 | 0.86 |
| Verwaterde WPA
| -0.09 | -0.081 | -0.19 | 0.015 | 0.062 | 0.046 | 0.3 | 0.38 | 0.46 | 0.91 | 0.84 | 0.86 |
| EBITDA
| 0.361 | -11.7 | -23.787 | 14.302 | 22.517 | 31.331 | 73.22 | 76.653 | 90.106 | 135.287 | 119.506 | 110.362 |
| EBITDA ratio
| 0.004 | -0.088 | -0.139 | 0.067 | 0.077 | 0.078 | 0.268 | 0.278 | 0.338 | 0.399 | 0.401 | 0.387 |